The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-05-02

Study Completion Date

2021-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A double-blind, randomized, placebo-controlled, crossover design trial was used to test the effect of exenatide on alcohol self-administration and craving following a priming dose of alcohol. The specific objective of this research was to determine whether exenatide has effects on alcohol consumption.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?

NCT03232112

Alcohol Dependence, in Remission Addiction, Alcohol

COMPLETED PHASE2

Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

NCT05895643

Alcohol Abuse Alcohol Addiction Alcohol Dependence +1 more

COMPLETED PHASE2

Pitolisant Effects on Alcohol Self-Administration in Heavy Drinkers

NCT04596267

Alcohol Use Disorder Alcohol Drinking

TERMINATED PHASE1

A Study of Brenipatide in Participants With Alcohol Use Disorder

NCT07219953

Alcohol Use Disorder

RECRUITING PHASE3

Semaglutide for Alcohol Use Disorder

NCT05520775

Alcohol Use Disorder Cigarette Smoking

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This proposal was intended to answer the call for accelerating drug development by exploring the potential of a glucagon-like peptide-1 (GLP-1) agonist, exenatide, as a candidate medication for the treatment of Alcohol Use Disorder. There is now substantial preclinical evidence that GLP-1 agonists can attenuate behaviors that model both the consumption and seeking of several commonly abused substances including alcohol, cocaine, and nicotine. This study was intended to accelerate medication development for Alcohol Use Disorder by testing a commercially-available and well-tolerated agent at a fraction of the cost of new drug discovery. None of the FDA-approved Alcohol Use Disorder medications or off-label Alcohol Use Disorder medications target this GLP-1 pathway, making exenatide a promising compound for Alcohol Use Disorder drug development.

The primary aim of this study was to test the effects of exenatide on alcohol self-administration and craving among heavy drinkers. In this within-subjects crossover design, 3 heavy drinkers were randomized to exposure order (exenatide or sham injection) prior to completing two alcohol self-administration trials. Subjects received a priming drink of alcohol and had access to 8 drinks over a 2-hour period. The investigators anticipated that subjects would consume less alcohol following the administration of exenatide compared to when they received a sham injection. Significant exenatide-induced reductions in drinking would be considered to be an indication that this drug may have value as an Alcohol Use Disorder medication. This study may provide a rationale for phase II randomized controlled trials testing exenatide with a treatment-seeking Alcohol Use Disorder population. These results may also help to spur further clinical investigation of the effects of exenatide and other available GLP-1 agonists on the factors implicated in the regulation of alcohol consumption.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcohol Use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

This is a double-blind, randomized, placebo-controlled, crossover design trial that tested the effect of exenatide on alcohol self-administration and craving following a priming dose of alcohol.

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Nursing staff at the general Clinical Research unit were not blinded to the study medication. These nurses' only role in the study was providing injections of the study drug. All other staff were blinded to medication assignments. The sham injection was a needlestick using the exenatide multi-dose syringe with no drug injected. Note that the volume of fluid injected for a 5mcg dose was only .08ml. It is not expected that subjects would sense this volume of fluid (or lack thereof) during the injection. Subjects were shielded from seeing the injection to maintain the blind. The individual who administered medication did not participate in subject evaluation to maintain the study blind.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exenatide then Placebo

This is a within subjects design study in which each subject receives both study drug and placebo. Subjects in this arm received a 5 mcg dose of immediate release exenatide on the day of the first alcohol self-administration trial. The 5mcg dose of exenatide was approved as the first dose administered to patients at the start of their treatment with this drug for FDA-approved indications. Subjects in this arm then received a sham injection on the day of the second alcohol self-administration trial. The sham injection was a needle stick using a syringe with no drug injected. Note that the volume of fluid injected for a 5mcg dose is so small that subjects would not sense this volume of fluid (or lack thereof) during the injection. Subjects were shielded from seeing the injection to maintain the blind.

Group Type EXPERIMENTAL

Exenatide

Intervention Type DRUG

Subject received an injection of 5 mcg of immediate release exenatide.

Sham injection

Intervention Type OTHER

Subjects received a sham injection with no study drug.

Placebo then Exenatide

This is a within subjects design study in which each subject receives both study drug and placebo. Subjects in this arm received a sham injection on the day of the first alcohol self-administration trial. The sham injection was a needle stick using a syringe with no drug injected. Subjects in this arm then received a 5 mcg dose of immediate release exenatide on the day of the second alcohol self-administration trial. The 5mcg dose of exenatide was approved as the first dose administered to patients at the start of their treatment with this drug for FDA-approved indications. Note that the volume of fluid injected for a 5mcg dose is so small that subjects would not sense this volume of fluid (or lack thereof) during the injection. Subjects were shielded from seeing the injection to maintain the blind.

Group Type EXPERIMENTAL

Exenatide

Intervention Type DRUG

Subject received an injection of 5 mcg of immediate release exenatide.

Sham injection

Intervention Type OTHER

Subjects received a sham injection with no study drug.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exenatide

Subject received an injection of 5 mcg of immediate release exenatide.

Intervention Type DRUG

Sham injection

Subjects received a sham injection with no study drug.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Byetta Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 21-55 years of age.
2. Able to verify age with a state or federal picture identification.
3. Exceeds safe weekly drinking limits \[4 standard drink units (SDUs) for women or 21 SDUs for men per week\]
4. Reports at least one episode of binge drinking (\>3 SDUs for women, \>4 SDUs for men) an average of once per week in the four weeks prior to baseline screening.
5. Meets Diagnostic And Statistical Manual Of Mental Disorders, Fifth Edition (DSM-5)criteria for mild alcohol use disorder or greater severity.

Exclusion Criteria

1. Seeking treatment for alcohol problems.
2. Clinical Institute Withdrawal Assessment at ≥10
3. DSM-5 diagnosis of current major depression, bipolar disorder, schizophrenia, bulimia/anorexia, dementia, or a substance use disorder other than alcohol, nicotine, marijuana or caffeine.
4. If female, pregnant, nursing, have plans to become pregnant.
5. If female, does not agree to use an accepted form of birth control.
6. Has a medical contraindication to the use of exenatide.
7. Has medical or mental condition for which further alcohol exposure at the planned dose range would be contraindicated.
8. Current risk of suicidality (MINI suicidality score greater than 8 (low risk) or Yes to the ideation question #4 of the C-SSRS).
9. BMI is less than 18 or greater than or equal to 30.
10. History of diabetes.
11. Baseline hemoglobin A1c ≥ 6.5%
12. Baseline non fasting glucose \>200
13. Significantly elevated serum lipase levels.
14. Impaired renal function (GFR \<80 mL/min).
15. Pancreatitis, gastroparesis or other severe gastrointestinal disease.
16. Has had gastric bypass surgery
17. Subject is currently taking warfarin.
18. Has received alcohol counseling or other non-pharmacologic intervention to treat AUD in the past 90 days.
19. Has taken medications that are used to treat alcohol use disorder (AUD) in the past 90 days.
20. Subjects with a history of thyroid cancer or other thyroid disease.
21. Has urine toxicology results positive for cocaine, opioids, amphetamines, buprenorphine, methadone, or methamphetamines.
22. Prior history of anaphylaxis or angioedema with another GLP-1 receptor agonist.
23. Prior use of exenatide
24. Liver function values AST or ALT are twice the normal limit
25. Unable to comfortably abstain from nicotine for a period of 8 hours.
26. Has Chronic obstructive pulmonary disease (COPD), history of solid organ transplant, sickle cell disease, severe heart disease or other health condition for which exposure to COVID-19 represents an unreasonable risk as determined by the study staff physician using accepted COVID-19 guidance (e.g. Centers for Disease Control, etc.).
27. Subject has prior history of Drug-induced thrombocytopenia

Minimum Eligible Age

21 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes